Related Experiment Videos
[Value of thrombolytic therapy in childhood]
1Abt. III Pädiatrische Kardiologie, Medizinischen Hochschule, Hannover.
Insights
Fibrinolytic therapy in infants and children differs from adults, primarily treating catheter-associated thrombosis in newborns and arterial clots post-cardiac catheterization in older children. Guidelines and dosages are provided for streptokinase, urokinase, and recombinant tissue plasminogen activator.
Area of Science:
- Pediatric Thrombosis and Hemostasis
- Pharmacology and Therapeutics
Background:
- Fibrinolytic therapy indications in pediatric patients vary significantly compared to adults.
- Common indications include catheter-associated thrombosis in neonates and arterial thrombosis post-cardiac catheterization in young children.
Purpose of the Study:
- To provide evidence-based guidelines and dosage recommendations for fibrinolytic therapy in infants and young children.
- To outline systemic and local treatment approaches using streptokinase, urokinase, and recombinant tissue plasminogen activator.
Main Methods:
- Review of current literature on pediatric fibrinolytic therapy.
- Incorporation of clinical experience and case data.
- Development of treatment guidelines and dosage recommendations.
Main Results:
- Established distinct indications for fibrinolytic therapy in neonates versus young children.
- Provided specific dosage recommendations for systemic and local administration of various fibrinolytic agents.
- Highlighted the importance of catheter-associated thrombosis and post-cardiac catheterization thrombosis as key indications.
Conclusions:
- Fibrinolytic therapy in pediatric populations requires tailored approaches based on age and indication.
- Guidelines and dosage recommendations are crucial for effective and safe treatment of thrombosis in infants and children.
- Streptokinase, urokinase, and recombinant tissue plasminogen activator are key agents for pediatric fibrinolysis.
Abstract:
Indications for fibrinolytic therapy in infants and young children differ significantly from those in adults. In preterm and newborn infants, it is mostly the catheter-associated thrombosis following catheterisation of the umbilical artery or vein that requires fibrinolytic therapy. In young children the main indication is arterial thrombosis after cardiac catheterisation. Based on the current literature and our own experience guidelines as well as recommendations for dosages are given for systemic and local therapy with streptokinase, urokinase and recombinant tissue plasminogen activator.